320 mg/day of liposterolic extract.
⏱ 3 min read
Saw palmetto is Serenoa repens, a dwarf palm native to the southeastern United States whose ripe fruits (oily drupes) have been used traditionally by Native Americans and later by European medicine to treat male urinary and reproductive problems; the standardized lipid extract of the fruit is one of the most widely used herbal therapies worldwide as a symptomatic treatment for mild to moderate benign prostatic hyperplasia, alongside Pygeum africanum, nettle root, and beta-sitosterol, and as an optional treatment for male androgenetic alopecia.
The identified active components are free fatty acids (especially lauric, myristic, oleic, and palmitic acids), sterols, fatty alcohols, and other lipid compounds with documented activity on multiple mechanisms related to prostatic hyperplasia: mild inhibition of 5-alpha-reductase types I and II (the enzyme that converts testosterone into dihydrotestosterone, the main androgen responsible for prostate growth), modest antiandrogenic activity, local anti-inflammatory activity, modulation of the androgen receptor, and other effects on urinary function; together, these mechanisms explain the clinical profile of gentle modulation of prostatic symptoms.
The traditional and most studied indication is symptomatic mild to moderate benign prostatic hyperplasia: several meta-analyses have documented significant improvements in symptom scales (IPSS), urinary flow, and postvoid residual volume with doses of 320 milligrams per day of standardized lipid extract for 6-8 weeks; the effects are quantitatively smaller than those of pharmacological alpha-blockers (tamsulosin) or 5-alpha-reductase inhibitors (finasteride, dutasteride), but sufficient as a first option in mild to moderate benign hyperplasia with good tolerability.
However, the large modern trials with better methodological quality (especially CAMUS, published in JAMA in 2011, with 369 patients and 18 months of follow-up) have shown unfavorable results: saw palmetto at 320 mg/day (the standard dose) and at increasing doses up to 960 mg/day was not significantly superior to placebo in symptomatic or functional improvements in moderate to severe benign prostatic hyperplasia; these results have considerably tempered clinical expectations for saw palmetto, positioning it as a reasonable option only for mild benign hyperplasia and without expecting effect sizes comparable to specific drugs.
In male androgenetic alopecia, several small studies have documented modest improvements in hair parameters with oral saw palmetto supplementation over months; the effects are quantitatively smaller than those of pharmaceutical finasteride (the drug treatment of choice) but may have a place as a first-line option in very mild alopecia or as an adjunct; topical formulations with saw palmetto are an emerging option with preliminary clinical data.
The dose studied is 320 milligrams per day of standardized lipid extract (with a minimum of 85-95 percent free fatty acids and sterols), in a single dose or split into two doses with meals to improve absorption (the components are lipophilic and are better absorbed with dietary fat); the effect on prostatic symptoms appears gradually and requires at least 6-8 weeks for initial clinical evaluation; commercial products without lipid standardization are significantly less effective.
Generally well tolerated; the most frequent adverse effects are mild digestive discomfort (nausea, dyspepsia, diarrhea), reported in approximately 5 percent of users; sporadic cases of mild hepatotoxicity have been described with prolonged use and, rarely, gynecomastia or changes in libido (attributable to the modest antiandrogenic effect); people taking pharmacological alpha-blockers (tamsulosin, doxazosin) or 5-alpha-reductase inhibitors (finasteride, dutasteride) may combine them with saw palmetto under medical supervision, although it is not usual for it to provide additional benefits over the specific drug treatment; those taking anticoagulants should be theoretically cautious because of a described mild antiplatelet effect; people with prostate cancer or clinical suspicion of it should be evaluated by urology before starting saw palmetto (saw palmetto slightly lowers PSA, which can mask early detection of cancer); in pregnancy and breastfeeding, data are limited although the indication is clearly male; it is not recommended under age 18; products without standardization in free fatty acids and sterols have highly variable clinical efficacy; the reasonable clinical stance is: in mild benign prostatic hyperplasia with modest symptoms and a patient preference for herbal therapy, saw palmetto is an acceptable option; in moderate to severe hyperplasia, the CAMUS data and other trials suggest that specific pharmacological interventions are superior and should be the first clinical choice.
Information, not medical advice. Scientific evidence reflects the quality of the studies.